Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Videos

The neurosurgeon at Northwestern Medicine discussed diagnostic approaches, evolving treatment strategies, and the importance of timely referral in managing peripheral nerve injuries. [WATCH TIME: 3 minutes]

Emerging Considerations in Peripheral Nerve Injury and Surgical Intervention: Kevin Swong, MD

Articles

The trial of the H₃ inverse agonist aims to evalute its ability to reduce cataplexy and improve symptoms in patients with narcolepsy type 1.

Phase 2 Study to Test Therapeutic Potential of Samelisant for Narcolepsy Type 1

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.

National RLS Registry Provides Long-Term Insights Into Opioid Use for Restless Legs Syndrome

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]

Rationale Behind NVG-2089 as New Therapy for CIDP: Pamela Conley; Alan Glicklich, MD

Marco Meglio, Assistant Managing Editor for 

, has been with the team since October 2019. Follow him on Twitter 

The neuroscientist and physician at Mount Sinai explored the role of sleep-dependent brain clearance in Alzheimer disease and how emerging research is challenging longstanding assumptions.

NeuroVoices: Andrew Varga, MD, on Debating Whether Brain Cleansing Prevents Alzheimer Disease

Senior Director, Patient Management, Care and Rehabilitation Research, National MS Society

The associate vice president of research at the National MS Society discussed a growing research initiative focused on defining and promoting evidence-based psychosocial wellness strategies for individuals with MS. [WATCH TIME: 6 minutes]

Expanding the Scope of Wellness Research in Multiple Sclerosis: Kathy Zackowski, PhD, OTR

Founder and Executive Director, Sumaira Foundation

The executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]

Investigating Treatment Differences of Off-Label and Marketed Therapies for NMOSD: Sumaira Ahmed

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Treatment Advances in Targeting Underlying Pathophysiology of Myasthenia Gravis

Generalized Myasthenia Gravis Pipeline

Video content above is prompted by the following:

Which emerging agents in gMG are you excited about?

Nicholas J. Silvestri, MD, FAAN; Ali A. Habib, MD; Neelam Goyal, MD; and Katherine Ruzhansky, MD, MS, explore the multifaceted aspects of generalized myasthenia gravis, from its clinical presentation and diagnosis to emerging targeted therapies, emphasizing the importance of personalized treatment approaches, discussing recent clinical trial data, and addressing ongoing challenges in both adult and pediatric populations.

Panelists discuss how myasthenia gravis presents clinically in adults and children, factors contributing to its underdiagnosis, and symptoms that should prompt specialist consultation.

Generalized Myasthenia Gravis Presentation and Diagnosis

Panelists discuss how the classification of generalized myasthenia gravis (gMG) informs and guides treatment strategies for patients.

Generalized Myasthenia Gravis Classification and Treatment Strategy

Panelists discuss how the current understanding of myasthenia gravis pathophysiology is informing the development of targeted treatments, alongside reviewing the standard of care for generalized myasthenia gravis (gMG).

Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

Panelists discuss how various outcome measures are utilized in clinical practice to assess and monitor patients with generalized myasthenia gravis.

Outcome Measures in Generalized Myasthenia Gravis

Panelists discuss how complement inhibitors work to treat generalized myasthenia gravis (gMG), evaluating their efficacy and safety profiles based on FDA approvals and clinical experience.

Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

Panelists discuss how various approved and investigational FcRn-targeting agents differ in their mechanisms of action for treating generalized myasthenia gravis (gMG).

Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

Panelists discuss how specific disease characteristics and individual patient factors influence their decision-making process when selecting treatments for generalized myasthenia gravis.

Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

Panelists discuss how they approach combination therapy in generalized myasthenia gravis (gMG), including patient selection and timing, while also examining how the availability of newer targeted treatments has influenced their approach to managing newly diagnosed patients.

Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

Panelists discuss how recent phase 3 trial results for nipocalimab and batoclimab, both neonatal Fc receptor (FcRn) inhibitors, demonstrate efficacy and safety in different generalized myasthenia gravis patient populations, comparing these findings with earlier phase 2 data and evaluating their potential impact on treatment approaches.

Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

Panelists discuss how they approach and potentially adapt the dosing and administration regimens of approved and investigational FcRn inhibitors in their myasthenia gravis patients, considering the prescribed guidelines and individual patient needs.

Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

Panelists discuss how they select patients for FcRn and complement inhibitor therapies, integrate these treatments into long-term management plans, monitor patients on these therapies, and approach treatment for those with inadequate disease control on traditional or targeted therapies for generalized myasthenia gravis.

Use of Targeted Agents in Generalized Myasthenia Gravis

Panelists discuss how generalized myasthenia gravis (gMG) presents unique diagnostic challenges in pediatric populations, review current standard-of-care management strategies for children and adolescents, and highlight promising investigational treatments for pediatric gMG.

Management of Generalized Myasthenia Gravis in Pediatric Patients

Panelists discuss how certain aspects of myasthenia gravis management remain challenging, identifying ongoing unmet needs in diagnosis, treatment, and patient care.

Unmet Needs in Generalized Myasthenia Gravis

Panelists discuss how emerging agents for generalized myasthenia gravis (gMG) show promise in addressing current treatment gaps, highlighting specific therapies they find particularly exciting for future management of the condition.

Panelists discuss how recent data presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) conference may impact clinical practice for myasthenia gravis, highlighting emerging treatments they find particularly promising for future management of the condition.

New Data from AANEM 2024 in Generalized Myasthenia Gravis

Panelists discuss how a multidisciplinary approach involving various specialists is crucial in managing generalized myasthenia gravis (gMG), offering final insights and recommendations for health care professionals treating gMG patients.

Clinical Pearls for Management of Generalized Myasthenia Gravis

Peer Exchange

The landscape of generalized myasthenia gravis (gMG) treatment is evolving with the introduction of novel therapeutic agents. These emerging treatments focus on targeting specific pathways involved in the disease's pathophysiology, offering potential improvements in efficacy and safety profiles compared to traditional therapies. Among the promising agents are complement inhibitors, FcRn antagonists, and other biologics that modulate immune responses. These advancements hold the potential to significantly enhance patient outcomes, reduce disease burden, and provide more personalized treatment options for individuals with gMG.

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Generalized Myasthenia Gravis Pipeline

Key Takeaways

EP: 1.Generalized Myasthenia Gravis Presentation and Diagnosis

EP: 2.Generalized Myasthenia Gravis Classification and Treatment Strategy

EP: 3.Pathophysiology and Standard of Care in Generalized Myasthenia Gravis

EP: 4.Outcome Measures in Generalized Myasthenia Gravis

EP: 5.Complement Inhibitors for Treatment of Generalized Myasthenia Gravis

EP: 6.Neonatal Fc Receptors in Treatment of Generalized Myasthenia Gravis

EP: 7.Factors Guiding Treatment Selection in Generalized Myasthenia Gravis

EP: 8.Combination Therapy in Generalized Myasthenia Gravis and Treatment of Newly Diagnosed Patients

EP: 9.Nipocalimab and FcRn Inhibitors in Generalized Myasthenia Gravis

EP: 10.Dosing Regimens and Treatment Efficacy of FcRn Inhibitors in Generalized Myasthenia Gravis

EP: 11.Use of Targeted Agents in Generalized Myasthenia Gravis

EP: 12.Management of Generalized Myasthenia Gravis in Pediatric Patients

EP: 13.Unmet Needs in Generalized Myasthenia Gravis

EP: 14.Generalized Myasthenia Gravis Pipeline

EP: 15.New Data from AANEM 2024 in Generalized Myasthenia Gravis

EP: 16.Clinical Pearls for Management of Generalized Myasthenia Gravis

Newsletter